With regulators encouraging the use of non-animal methods including organoids and AI-based computational models in monoclonal antibody therapies, and analysis tools to characterize models becoming more accessible, it has never been more important for biopharma to gain clarity on best practice in tumor modeling and model selection strategies to achieve clinical translatability.

With these needs in mind, the 13th Tumor Models Summit Boston returned in July 2025 to provide an update on tumor model advancements, and how they can complement existing models to increase clinical confidence and relevancy of your candidate; and offered a chance to be part of the dialogue advancing bench-to-bedside development for safe and efficacious candidate selection.

With brand new content spanning tumor biology through to toxicology and therapeutic development, here’s what you missed: